阿爾法企業(00948.HK)下調向BUBS Australia全年採購目標
阿爾法企業(00948.HK)公布,其間接全資附屬維勒斯貿易與BUBS Australia訂立修訂契據,以將有關期間的2022年採購目標,由不少於5,000萬澳元下調至4,400萬澳元(約由2.7億港元下調至2.34億港元),其乃參考近期BUBS Australia可供應予集團的產品減少情況後釐定。其他條款維持不變。
公司認為,由於2022年採購目標的修訂,降低集團以零代價認購954.16萬股Bubs股份的門檻,料有利於集團財務表示,及預期並不會對奶類產品業務的營運造成任何重大負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.